Effects of Polyphenol, Measured by a Biomarker of Total Polyphenols in Urine, on Cardiovascular Risk Factors After a Long-Term Follow-Up in the PREDIMED Study

Xiaohui Guo, Anna Tresserra-Rimbau, Ramón Estruch, Miguel A. Martínez-González, Alexander Medina-Remón, Olga Castañer, Dolores Corella, Jordi Salas-Salvadó, and Rosa M. Lamuela-Raventós

1Department of Nutrition and Food Science, XaRTA, INSA, School of Pharmacy, University of Barcelona, Barcelona, Spain
2Biomedical Research Networking Center-Physiopathology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute (ISCIII), Government of Spain, Madrid, Spain
3Department of Internal Medicine, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
4Department of Preventive Medicine and Public Health, School of Medicine, University of Navarra, Pamplona, Spain
5IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
6Cardiovascular Risk and Nutrition Research Group (CARIN, Regicor Study Group), Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
7Department of Epidemiology, Preventive Medicine and Public Health, School of Medicine, University of Valencia, Valencia, Spain
8Human Nutrition Unit, University Hospital of Sant Joan de Reus, Department of Biochemistry and Biotechnology, Faculty of Medicine and Health Sciences, IISPV, Rovira i Virgili University, Reus, Spain

Correspondence should be addressed to Rosa M. Lamuela-Raventós; lamuela@ub.edu

Received 24 August 2015; Revised 16 October 2015; Accepted 21 October 2015

1. Introduction

Cardiovascular diseases (CVDs) are considered to be the leading global cause of death, accounting for 17.3 million deaths per year, which is predicted to rise to more than 23.6 million by 2030 [1]. The main causes of CVDs involve nonmodifiable risk factors, such as age, sex, and family history of coronary heart disease (CHD), and modifiable risk factors, such as an unhealthy diet, lack of physical activity, smoking, and excessive alcohol intake [2, 3]. Therefore, an improvement of dietary habits could help to prevent CVDs.
Several studies have described protective roles of polyphenols in the cardiovascular system. The cardiovascular protection by polyphenol consumption can be explained by various mechanisms, including their anti-inflammatory properties, antioxidant capacity, improvement in endothelial function, inhibition of platelet aggregation and antithrombotic properties, and mechanisms that are not mutually exclusive [4–8]. Hence, further exploration of polyphenol consumption will help to discern its beneficial effects on human health. Prior information on polyphenol intake has often been collected through food frequency questionnaires (FFQs) or dietary recalls, whose bias can result in data not so accurate [9]. Therefore, in order to analyse associations between polyphenol intake and main cardiovascular risk factors, there is a need for biomarkers that can accurately reflect polyphenol intake in human studies.

The Folin-Ciocalteu method, an antioxidant assay based on electron transfer that measures the reducing capacity of an antioxidant, has been widely applied for measuring total polyphenol content in plant-derived food and recently in biological samples for clinical studies [10, 11]. Briefly, polyphenols from urine samples react with the Folin-Ciocalteu reagent to form a blue complex in alkaline medium, measured in spectrophotometry at 765 nm [12]. A solid phase extraction method is used to clean up the sample from possible interferences. This measurement of total urinary polyphenol excretion (TPE) has been considered as a reliable biomarker of total polyphenol intake in recent years [8, 13, 14].

Several studies have addressed the relationship between polyphenol intake and cardiovascular risk factors; however, the results have led to mixed and inconsistent conclusions. Two studies conducted in healthy participants observed that improvement in cardiovascular health was due to higher HDL levels after intake of polyphenol-rich foods [15, 16]. Different results were obtained in other two studies in overweight subjects: one showed cardioprotective effects due to a reduction in body weight and an improvement in total cholesterol and LDL concentration after ingestion of a polyphenol extract from Ecklonia cava, while the other study observed a reduction in fasting glucose concentration when supplied with polyphenol-rich dark chocolate [17, 18]. Additionally, reduction in systolic blood pressure was observed in hemodialysis patients after the consumption of a polyphenol-rich beverage for one year [19]. Moreover, in the frame of the PREDIMED study, we found that specific categories of polyphenols, calculated through yearly FFQs and the Phenol-Explorer database, were significantly associated with decreased CVD risk [20].

Most of the aforementioned studies were conducted in small populations or over short periods of time. The association between polyphenol intake and cardiovascular risk factors has also been evaluated in large, long-term epidemiological trials, but with the limitations associated with using FFQs [21–24]. Therefore, the aim of the present study was to apply the reliable and validated antioxidant activity test, the Folin-Ciocalteu method, in urine samples as a biomarker of total polyphenol intake, to analyse the association between polyphenol intake and cardiovascular risk factors in an elderly population at high cardiovascular risk after a long-term follow-up (median: 4.8 years).

2. Methods

The present study was conducted within the frame of the PREDIMED study, which aimed to assess effects of the Mediterranean diet on the primary prevention of CVDs in Spain. The protocol and recruitment methods have been reported in detail elsewhere [25]. Eligible participants were men aged 55–80 and women aged 60–80 years without any history of cardiovascular disease but fulfilling at least one of the following two criteria: type-2 diabetes or three or more cardiovascular risk factors (family history of early-onset CVDs, hypertension, current smoking, low HDL-cholesterol, high LDL-cholesterol, and overweight or obesity). Exclusion criteria included any severe chronic illness, previous history of CVDs, alcohol or drug abuse, body mass index (BMI) of more than 40 kg/m², and history of allergy or intolerance to olive oil or nuts. The trial was stopped after a median follow-up of 4.8 years due to the benefit of the Mediterranean diet with respect to major cardiovascular events: myocardial infarction, stroke, or death from cardiovascular causes (analysis performed by the Drug and Safety Monitoring Board of the trial), compared to a control low-fat diet [26].

The present longitudinal analysis included 612 volunteers, randomly selected from two recruitment centers in Spain. All participants provided written informed consent, and the protocol was approved by the Institutional Review Boards of the participating centers and registered.

2.1. Nutritional Assessments. Dietary habits of participants were assessed through a validated 137-item FFQ [27]. Nutrient intake was adjusted by calories using the residuals' method. Information about lifestyle, health condition, education, history of illnesses, and medication use was collected by a 47-item general questionnaire. The degree of adherence to the Mediterranean diet was assessed by a 14-point questionnaire [28]. Physical activity was assessed using the validated Spanish version of the Minnesota Leisure-Time Physical Activity Questionnaire [29]. All questionnaires were administered and repeated annually during the follow-up by trained staff in face-to-face interviews.

Information on polyphenol intake was obtained using the FFQ and the Phenol-Explorer database. The relationship between food items in the FFQ and the database has been described previously [30]. The content of total polyphenol intake equals the sum of all the individual polyphenol from each food item.

2.2. TPE Measurements. Urine samples were collected and coded and then immediately shipped to a central laboratory, to be stored at −80°C until analysed. The Folin-Ciocalteu method was applied to determine the content of TPE, using a clean-up procedure with solid phase extraction (SPE) performed in 96-well plate cartridges (Oasis MAX), which helped to remove urinary interferences. Finally, TPE was expressed as mg gallic acid equivalent (GAE)/g of creatinine.
All details have been previously described by Medina-Remón et al. [14].

2.3. Clinical Measurements. Weight and height were measured with light clothing and no shoes with a calibrated balance and a wall-mounted calibrated stadiometer, respectively. BMI was calculated as weight in kilograms divided by the square of height in meters. For the measurement of blood pressure (BP), a validated semiautomatic sphygmomanometer (Omron HEM-705CP) was used by trained nurses. Measurements were taken at 5-minute intervals with participants in a seated position. Data were collected as an average of 2 measurements in each arm, repeated twice [31].

Plasma glucose, total cholesterol, and triglyceride concentrations were measured using standard enzymatic automated methods. Levels of HDL-cholesterol were measured by an enzymatic procedure after precipitation, and LDL-cholesterol was estimated by the Friedewald formula [32].

2.4. Statistical Analysis. Results were expressed as mean ± SD for continuous variables or percentages for categorical variables. Kolmogorov tests were applied to examine the normality distribution and skewness. All participants were divided into three categories according to changes in TPE during the follow-up (ΔTP < −11.4 mg gallic acid/g creatinine, −11.4 ≤ ΔTP ≤ 24.6 mg gallic acid/g creatinine, and ΔTP > 24.6 mg gallic acid/g creatinine). Changes in nutrient and key food consumption during the follow-up were assessed with ANOVA for repeated measurements analysis. Bonferroni post hoc test and paired t-test were used to compare each variable within and between groups.

Multivariate linear regression models were used to assess the relationship between serum glucose, total cholesterol, HDL, LDL, triglyceride concentrations, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate, and tertiles of changes in TPE during the follow-up period, adjusted for potential confounders (sex, age, intervention groups, BMI, smoking status, family history of CHD, physical activity, hypertension, diabetes, dyslipidemia, medication use, and 14-unit Mediterranean diet score at baseline). Sensitivity analyses were used to further assess the relationship between specific cardiovascular risk factors and subcategories.

General Linear Model (GLM) approach to ANCOVA was used to determine differences between tertiles of changes in TPE after 5-year follow-up, adjusted for potential confounders as did in multivariate linear regression models.

All analyses were performed using SPSS software V21.0 (Chicago, USA). All models were tested for the detection of outliers, multicollinearity, homoscedasticity, and normality and independence of errors. All statistical tests were two-tailed, and the significance level was $P < 0.05$.

3. Results

After 5 years of follow-up of 612 participants randomly selected for this substudy of the PREDIMED trial, 39 were excluded because of extreme TPE values, hence a total of 573 participants were included in the present study. Baseline characteristics of participants grouped by tertiles of changes in TPE during the follow-up are shown in Table 1. According to the study design, the average age was 67.3 ± 5.9 years with a BMI of 29.2 ± 3.3 kg/m². Most of the participants gathered a high number of cardiovascular risk factors: 41.5% had diabetes; 80.5% had hypertension; 66.8% had dyslipidemia; 16.9% were current smokers, and 37.5% had a family history of CHD. In the second tertile, individuals were less likely to be women and had a higher body weight. Table 2 shows changes in key food consumption during the follow-up. Most key foods changed considerably after the long-term intervention, with the exception of legumes and chocolate. Table 3 summarizes information on nutrient intake at baseline and 5 years according to changes in TPE during the follow-up. Comparing nutrient intake at 5 years versus baseline, we observed a significant increase in total fat, fibre, monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA), K, and Mg, while other items such as total carbohydrates, protein, saturated fatty acids (SFA), Na, and cholesterol remained unchanged. This may be due to dietary changes based on recommendations to adhere to a Mediterranean diet, which is characterized by a high consumption of vegetables, fruits, olive oil, wine, and nuts and a low consumption of red meat, high-fat dairy products, and sweets. However, there were no significant changes when comparing tertiles and their interaction. In addition, we found that significant changes in TPE did not significantly affect the intake of nutritional elements among groups.

Several antioxidant substances such as sulfur dioxide, ascorbic acid, sugar, aromatic amines, organic acid, Fe(II), and nonphenolic organic substances might affect total polyphenol when applying Folin-Ciocalteu assay; however, after a solid phase extraction (SPE), the aforementioned interfering substances were eliminated through the cleaning-up process [14].

Linear regression analyses were conducted to assess the relationship between TPE ($Q_1 = −48.70 ± 30.11$ mg GAE/g creatinine; $Q_2 = 6.95 ± 10.55$ mg GAE/g creatinine; $Q_3 = 64.48 ± 31.61$ mg GAE/g creatinine) and clinical possible cardiovascular risk factors (plasma glucose, triglyceride, cholesterol, HDL-c, and LDL-c concentrations, and SBP, DBP, and heart rate). Results are shown in Table 4. Significant inverse associations were found between tertiles of changes in TPE and glucose ($β = −4.372; P = 0.026$), triglycerides ($β = −8.572; P = 0.006$), and DBP ($β = −1.156; P = 0.031$) after adjustment for potential confounders. However, other parameters did not show significant associations. The standardized coefficients (Beta) in the model were used to measure degrees of contribution to different risk factors. Results indicate that, among the CVD risk factors, triglyceride levels showed the highest beneficial effects of dietary polyphenol intake (Beta = −0.126; $P = 0.031$).

We also conducted sensitivity analyses to ascertain whether significant changes were related to specific variables. As shown in Table 5, men were more likely to improve their plasma triglyceride concentration than women, according to tertiles of changes in TPE. In contrast, the lowering effects
Table 1: Baseline characteristics of participants according to tertiles of changes in TPE.

| TPE (mg GAE/g creatinine) | Q₁ (ΔTP < -11.4) | Q₂ (-11.4 ≤ ΔTP ≤ 24.6) | Q₃ (ΔTP > 24.6) | P  |
|---------------------------|------------------|--------------------------|------------------|----|
| Number of subjects        | 191              | 191                      | 191              | 191 |
| Women, n (%)              | 101 (52.9)       | 83 (43.5)                | 112 (58.6)       | 0.011 |
| Age (y), mean (SD)        | 66.7 (5.9)       | 67.3 (5.8)               | 68.00 (6.0)      | 0.113 |
| Weight (kg), mean (SD)    | 73.9 (10.6)      | 77.1 (11.6)              | 74.5 (10.7)      | 0.01 |
| BMI (kg/m²), mean (SD)    | 28.9 (3.1)       | 29.6 (3.5)               | 29.2 (3.2)       | 0.103 |
| Systolic BP (mm Hg), mean (SD) | 149.8 (17.9)   | 151.6 (16.9)             | 152.8 (18.6)     | 0.238 |
| Diastolic BP (mm Hg), mean (SD) | 84.3 (9.8)    | 85.9 (10.0)              | 85.5 (10.4)      | 0.269 |
| Hypertension, n (%)       | 151 (79.1)       | 152 (79.6)               | 158 (82.7)       | 0.621 |
| Diabetes, n (%)           | 78 (40.8)        | 85 (44.5)                | 75 (39.3)        | 0.567 |
| Dyslipidemia, n (%)       | 136 (72.3)       | 117 (61.3)               | 128 (67)         | 0.074 |
| Smoking status            |                 |                          |                  | 0.641 |
| Current, n (%)            | 35 (18.3)        | 34 (17.8)                | 28 (14.7)        | 0.586 |
| Former, n (%)             | 36 (18.8)        | 43 (22.5)                | 47 (24.6)        | 0.388 |
| Never, n (%)              | 120 (62.8)       | 114 (59.7)               | 116 (60.7)       | 0.814 |
| Family history of CHD, n (%) | 65 (35.3)   | 75 (40.3)                | 75 (41.2)        | 0.460 |
| Medication                |                 |                          |                  |      |
| Aspirin, n (%)            | 33 (32.0)        | 35 (34.0)                | 35 (34.0)        | 0.949 |
| Antihypertensive drugs, n (%) | 131 (68.6)   | 142 (74.3)               | 141 (73.8)       | 0.381 |
| Hypolipidemic drugs, n (%) | 91 (47.6)      | 70 (36.6)                | 78 (40.8)        | 0.089 |
| Insulin, n (%)            | 10 (5.2)         | 9 (4.7)                  | 8 (4.2)          | 0.890 |
| Oral hypoglycemic drugs, n (%) | 40 (20.9)   | 46 (24.1)                | 45 (23.6)        | 0.736 |
| Vitamin or minerals, n (%) | 18 (9.5)        | 16 (8.5)                 | 13 (6.9)         | 0.644 |
| Educational level         |                 |                          |                  |      |
| Primary school, n (%)     | 140 (74.1)       | 139 (73.5)               | 146 (76.8)       | 0.793 |
| High school, n (%)        | 32 (16.9)        | 28 (14.8)                | 28 (14.7)        |      |
| University, n (%)         | 17 (9.2)         | 22 (11.6)                | 16 (8.4)         | 0.696 |
| Physical activity at leisure time (MET-min/d) | 275 (212) | 287 (204) | 269 (183) | 0.135 |
| Polyphenol intake (mg/d)  | 853.4 (239.8)    | 831.2 (248.9)            | 882.7 (247.8)    |      |

BMI: body mass index; CHD: coronary heart disease; GAE: gallic acid equivalent; TPE: total polyphenol excretion. Data are given as means (SD) for continuous variables and percentages for categorical variables; P < 0.05 indicates statistical significance. *P* values calculated by analysis of variance or χ² tests.

4. Discussion

In this 5-year study of an elderly population at high cardiovascular risk living in a Mediterranean country, we observed that higher polyphenol intake, measured by TPE, was inversely associated with some cardiovascular risk factors. The observed benefits on CVs were ascribable to a reduction in plasma glucose and triglyceride concentrations and a diminution of DBP. This may partly explain the decreased CVD risk shown by people following a polyphenol-rich diet such as the Mediterranean diet.

The beneficial effects of polyphenols consumption on major cardiovascular events in the PREDIMED cohort have been published before [20]. The difference between our findings and other reported results lies in the measurement of polyphenols in urine as biomarker of polyphenol intake. Given that more than 8000 phenolic structures exist in nature, beneficial effects from polyphenols depend on a variety of factors, including total intake, food cooking processes, digestion, absorption, metabolic pathways in vivo, or even differences between individuals [33]. Therefore, TPE, as a biomarker of total polyphenol intake, may provide a more accurate insight into the effects of polyphenols on CVs than other dietary assessment methods.

Previous clinical studies on the benefits of polyphenols on the cardiovascular system have provided inconsistent results. A 12-week follow-up clinical trial conducted in Korea reported a strong inverse association between consumption of polyphenol extracts from *Ecklonia cava* and serum glucose, SBP, and HDL concentration [17]. In contrast, a recent randomized control trial performed with 67 elderly men at high cardiovascular risk found an increase in HDL.
Table 2: Changes in daily intake of key foods after 5 years with energy adjustment categorized by tertile of changes in TPEa.

|                                | Q₁ (ΔTP < −11.4) | Q₂ (−11.4 ≤ ΔTP ≤ 24.6) | Q₃ (ΔTP > 24.6) | TPE (mg GAE/g creatinine) | pᵇ | Timeᶜ | Groupᵈ | Time * Groupᵉ |
|--------------------------------|------------------|-------------------------|-----------------|---------------------------|----|-------|--------|---------------|
| **Vegetables (g/d)**          |                  |                         |                 |                           |    |       |        |               |
| Baseline                      | 302.1            | 293.9                   | 340.7**         | 289.6                     |    | <0.001| 0.195  | 0.369         |
| 5 years                       | 366.0**          | 122.9                   | 115.8           | 354.3**                    |    |       |        |               |
| **Fruits (g/d)**              |                  |                         |                 |                           |    |       |        |               |
| Baseline                      | 346.3            | 354.7                   | 385.4           | 216.1**                    |    | <0.001| 0.477  | 0.103         |
| 5 years                       | 459.4**          | 181.4                   | 454.0**         |                            |    |       |        |               |
| **Legumes (g/d)**             | 18.7             | 19.2                    | 19.6            | 8.8                        |    | 0.445 | 0.149  | 0.736         |
| **Cereals (g/d)**             |                  |                         |                 |                           |    |       |        |               |
| Baseline                      | 240.0            | 242.9                   | 238.9           | 70.7                       |    | <0.001| 0.867  | 0.712         |
| 5 years                       | 366.0            | 122.9                   | 216.1**         | 63.0                       |    |       |        |               |
| **Milk (g/d)**                |                  |                         |                 |                           |    |       |        |               |
| Baseline                      | 368.8            | 385.4                   | 393.2           | 233.2                      |    | 0.005 | 0.300  | 0.166         |
| 5 years                       | 385.4            | 120.9                   | 158.8           |                            |    |       |        |               |
| **Meat (g/d)**                | 140.9            | 140.1                   | 138.0           | 45.3                       |    | <0.001| 0.992  | 0.431         |
| 5 years                       | 126.6**          | 41.9                    | 130.1           | 44.1                       |    |       |        |               |
| **Fish (g/d)**                | 94.7             | 90.4                    | 91.7            | 39.2                       |    | <0.001| 0.521  | 0.882         |
| 5 years                       | 101.4            | 98.8*                   | 97.8*           | 36.2                       |    |       |        |               |
| **Pastries (g/d)**            | 26.1             | 25.7                    | 26.6            | 25.1                       |    | 0.001 | 0.846  | 0.485         |
| 5 years                       | 20.1             | 23.1                    | 21.5            | 27.3                       |    |       |        |               |
| **EVOO (g/d)**                | 140.9            | 140.1                   | 138.0           | 45.3                       |    | <0.001| 0.992  | 0.431         |
| 5 years                       | 126.6**          | 41.9                    | 130.1           | 44.1                       |    |       |        |               |
| **Nuts (g/d)**                | 94.7             | 90.4                    | 91.7            | 39.2                       |    | <0.001| 0.521  | 0.882         |
| 5 years                       | 101.4            | 98.8*                   | 97.8*           | 36.2                       |    |       |        |               |
| **Wine (g/d)**                | 140.9            | 140.1                   | 138.0           | 45.3                       |    | <0.001| 0.992  | 0.431         |
| 5 years                       | 126.6**          | 41.9                    | 130.1           | 44.1                       |    |       |        |               |
| **Folic acid (µg/d)**         | 302.1            | 293.9                   | 340.7**         | 289.6                     |    | <0.001| 0.939  | 0.322         |
| 5 years                       | 366.0**          | 122.9                   | 115.8           | 354.3**                    |    |       |        |               |
| **Coffee (mL/d)**             |                  |                         |                 |                           |    |       |        |               |
| Baseline                      | 38.4             | 33.2                    | 44.2            | 47.2                       |    | 0.004 | 0.902  | 0.258         |
| 5 years                       | 27.4*            | 28.6                    | 30.7            | 48.8                       |    |       |        |               |
| **Chocolate (g/d)**           | 26.1             | 25.7                    | 25.1            | 25.1                       |    | 0.001 | 0.846  | 0.485         |
| 5 years                       | 20.1             | 23.1                    | 21.5            | 27.3                       |    |       |        |               |

aData are given as means (SD); P < 0.05 indicates statistical significance. EVOO: extra virgin olive oil; GAE: gallic acid equivalent; TPE: total polyphenol excretion. Values with asterisks are statistically different from baseline values by the paired-samples t-test (∗P < 0.05; ∗∗P < 0.01).

bData analysed by repeated-measures 2-factor ANOVA.

cComparison between the time before and after intervention.

dComparison between tertiles of TPE changes.

eComparison between measurements obtained before and after intervention and between tertiles of TPE changes.

Participants who increased their polyphenol intake showed a reduction in plasma glucose concentrations, adding to the evidence that polyphenol-rich diets protect the cardiovascular system by improvements in glycemic control. A similar clinical trial performed on 78 participants at high cardiovascular risk, administration of polyphenol-rich foods, improved glucose metabolism by increasing early insulin secretion and insulin sensitivity [36]. Another cross-sectional study in an elderly population reported that green tea consumption was inversely associated with fasting blood glucose concentrations, though without adjusting for potential...
Table 3: Changes in nutrient intake after 5 years with energy adjustment categorized by tertile of changes in TPE<sup>a</sup>.

| Nutrient                  | Baseline | 5 years | Mean    | SD      | Mean    | SD      | Mean    | SD      | Time<sup>c</sup> | Group<sup>d</sup> | Time * Group<sup>e</sup> |
|---------------------------|----------|---------|---------|---------|---------|---------|---------|---------|-----------------|----------------|---------------------|
| **Total carbohydrates (g/d)** | 235.6 36.5 | 239.7 63.1 | 235.0 68.9 | 235.6 61.0 | 0.736 0.964 | 0.41 |
| Protein (g/d)              | 88.4 36.5 | 94.5 18.6 | 92.7 19.5 | 94.4 17.7 | 0.12 0.649 | 0.498 |
| **Total fat (g/d)**        | 102.5 12.8 | 102.7 13.6 | 24.6 ** | 24.4 ** | <0.001 0.528 | 0.331 |
| **MUFA (g/d)**             | 53.5 13.6 | 58.3 ** 12.7 | 59.6 ** | 13.5 | 59.8 ** | 13.5 | <0.001 0.97 0.19 |
| **SFA (g/d)**              | 25.5 9.0 25.7 18.6 | 92.7 19.5 | 94.4 17.7 | 0.949 0.887 | 0.114 |
| **PUFA (g/d)**             | 58.4 14.7 | 59.0 14.7 | 15.7 6.1 | 15.6 5.4 | <0.001 0.716 | 0.675 |
| **Alcohol (g/d)**          | 41.4 5.2 42.0 5.2 | 13.3 4.8 | 14.4 | 0.039 0.979 | 0.75 |
| Fibre (g/d)                | 24.2 6.0 24.2 6.0 | 15.2 6.4 | 15.2 6.4 | <0.001 0.564 | 0.204 |
| Cholesterol (mg/d)         | 18.8 24.6 | 23.8 33.1 | 49.3 64.8 | 39.5 94.0 | 0.763 0.963 | 0.41 |
| Na (mg/d)                  | 2229.8 644 | 2230.8 728.0 | 2233.7 652.0 | 0.2 0.946 | 0.975 |
| K (mg/d)                   | 4230.9 723 | 4164.3 682.7 | 4300.6 796.1 | <0.001 0.234 | 0.542 |
| Mg (mg/d)                  | 359.5 62.7 358.4 58.1 | 367.1 61.8 | 367.1 61.8 | <0.001 0.432 | 0.365 |

SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, GAE: gallic acid equivalent; TPE: total polyphenol excretion.

<sup>a</sup>Data are given as means (SD); P < 0.05 indicates statistical significance. Values with asterisks are statistically different from baseline by paired-samples t-test (*P < 0.05; **P < 0.01).

<sup>b</sup>Data analysed by repeated measures 2-factor ANOVA.

<sup>c</sup>Comparison between the time before and after intervention.

<sup>d</sup>Comparison between tertile changes in TPE.

<sup>e</sup>Comparison between measures obtained before and after intervention and between tertiles of TPE changes.

confounders [37]. Despite the abundance of results from different clinical trials, animal models, and in vitro tests, the mechanisms for hypoglycemic effects of polyphenols still warrant discussion. Potential explanations for these putative protective effects include reduced absorption of total carbohydrate in the intestine, modulation of enzymes related to glucose metabolism, stimulation of insulin secretion, improvement of β-cell function and insulin action, reduction in oxidative stress, inhibition of glucose transport, and enhanced vascular function [36, 38–40].

Triglycerides are considered the highest source of energy, and inhibition of triglyceride absorption also plays a role in the prevention of CVDs [41]. In the present study, increasing polyphenol intake was inversely associated with triglyceride levels, in agreement with some previous studies. Sugiyama et al. investigated the inhibitory effect of oligomeric pro-pycyanidins from apples on triglyceride absorption, explained by the inhibition of pancreatic lipase activity in vivo and in animal models [42]. Data from animal models indicated that such lowering effects could be attributed to the very low-density lipoprotein (VLDL) secretion rates and a decrease in apolipoprotein B secretion [43]. In addition, a study of haemodialysis patients fed with polyphenol-rich pomegranate juice also reported improvements in triglyceride levels, but this was explained by an inhibition of intestinal absorption and clearance of plasma triglycerides in vivo[19]. The variety of plausible mechanisms put forward to explain these effects, such as absorption, metabolism, and elimination during metabolic processes, reflect the highly varied chemical structure of polyphenols. Unlike the current study, most clinical trials have focused on a single
polyphenol-rich food such as dark chocolate, wine, or green tea. Therefore, considering that the Mediterranean diet is a constellation of several polyphenol-rich foods, it is difficult to draw a single mechanism to explain the lowering effects found on triglycerides.

Hypertension is a well-established risk factor for CVDs [44]. There is evidence from our study and others that increasing polyphenol intake is associated with lower BP. Both DASH (Dietary Approaches to Stop Hypertension) and SUN (Seguimiento Universidad de Navarra) studies emphasize that the consumption of plant-derived foods, particularly fruits, vegetables, nuts, and olive oil, is inversely associated with BP [45–47]. We previously reported that greater TPE was inversely associated with BP [13]. However, we found significant associations only for DBP, and not SBP. Another PREDIMED clinical substudy based on a 4-year intervention also supports our findings [48]. Mechanisms of the BP lowering effect could involve endothelial nitric oxide (NO) production. NO plays a fundamental role in the regulation of the vascular system, and vascular homeostasis is achieved only when NO levels are adequate [6]. Briefly, polyphenols induce NO production by promoting endothelial nitric oxide synthase (eNOS) expression, generating vascular relaxing factors such as prostacyclin (PGI2) and

---

**Table 4:** Multivariate linear regression analyses with changes in cardiovascular risk factors as dependent variables and tertiles of changes in TPE in spot urine samples (mg GAE/g creatinine) as exposure variables, adjusted for potential confounders.

|                          | β     | SE   | Beta | Sig   | 95% CI          |
|--------------------------|-------|------|------|-------|-----------------|
| **Change in GLU (mg/dL)** |       |      |      |       |                 |
| Model 1                  | −0.164| 1.979| −0.095| 0.036 | −8.053 to −0.275|
| Model 2                  | −0.316| 1.981| −0.098| 0.030 | −8.208 to −0.424|
| Model 3                  | −0.355| 1.949| −0.099| 0.026 | −8.186 to −0.525|
| Model 4                  | −0.372| 1.953| −0.099| 0.026 | −8.209 to −0.534|
| **Change in COL (mg/dL)** |       |      |      |       |                 |
| Model 1                  | −0.51 | 2.001| −0.057| 0.210 | −6.442 to 1.421 |
| Model 2                  | −2.236| 2.011| −0.050| 0.267 | −6.187 to 1.715 |
| Model 3                  | −1.845| 2.013| −0.042| 0.360 | −5.800 to 2.109 |
| Model 4                  | −1.802| 2.015| −0.041| 0.372 | −5.762 to 2.157 |
| **Change in HDL (mg/dL)** |       |      |      |       |                 |
| Model 1                  | 0.102 | 0.448| 0.010| 0.820 | −0.778 to 0.982 |
| Model 2                  | 0.135 | 0.448| 0.014| 0.763 | −0.744 to 1.015 |
| Model 3                  | 0.133 | 0.456| 0.014| 0.771 | −0.764 to 1.030 |
| Model 4                  | 0.174 | 0.454| 0.018| 0.701 | −0.718 to 1.067 |
| **Change in LDL (mg/dL)** |       |      |      |       |                 |
| Model 1                  | −0.205| 1.775| −0.005| 0.908 | −3.693 to 3.283 |
| Model 2                  | −0.039| 1.784| −0.001| 0.983 | −3.545 to 3.467 |
| Model 3                  | 0.448 | 1.783| 0.012| 0.802 | −3.056 to 3.952 |
| Model 4                  | 0.469 | 1.786| 0.012| 0.793 | −3.041 to 3.797 |
| **Change in TG (mg/dL)** |       |      |      |       |                 |
| Model 1                  | −8.356| 3.06 | −0.123| 0.007 | −14.369 to −2.344|
| Model 2                  | −8.563| 3.058| −0.126| 0.005 | −14.572 to −2.554|
| Model 3                  | −8.627| 3.094| −0.127| 0.006 | −14.708 to −2.546|
| Model 4                  | −8.572| 3.099| −0.126| 0.006 | −14.662 to −2.483|
| **Change in SBP (mm Hg)** |       |      |      |       |                 |
| Model 1                  | −1.367| 0.994| −0.058| 0.169 | −3.319 to 0.585 |
| Model 2                  | −1.222| 1.001| −0.052| 0.222 | −3.188 to 0.744 |
| Model 3                  | −1.127| 1.003| −0.048| 0.262 | −3.098 to 0.843 |
| Model 4                  | −1.098| 1.005| −0.046| 0.275 | −3.071 to 0.876 |
| **Change in DBP (mm Hg)** |       |      |      |       |                 |
| Model 1                  | −1.316| 0.531| −0.104| 0.013 | −2.359 to −0.273|
| Model 2                  | −1.254| 0.532| −0.099| 0.019 | −2.298 to −0.209|
| Model 3                  | −1.153| 0.532| −0.091| 0.031 | −2.198 to −0.108|
| Model 4                  | −1.156| 0.533| −0.091| 0.031 | −2.203 to −0.109|
| **Change in HR**         |       |      |      |       |                 |
| Model 1                  | −0.002| 0.555| 0.000| 0.997 | −1.091 to 1.087 |
| Model 2                  | 0.043 | 0.559| 0.003| 0.938 | −1.055 to 1.142 |
| Model 3                  | −0.011| 0.567| −0.001| 0.985 | −1.125 to 1.103 |
| Model 4                  | −0.074| 0.565| −0.006| 0.895 | −1.184 to 1.035 |

| GLU: glucose, COL: total cholesterol, LDL: high-density lipoprotein, HDL: low-density lipoprotein, TG: triglycerides, SBP: systolic blood pressure, DBP: diastolic blood pressure, and HR: heart rate. |
| β: nonstandardized coefficient (regression line coefficient); SE: standard error; Beta: standardized coefficient; CI: confidence interval; P: two-sided test of significance. |

Model 1: unadjusted; Model 2 adjusted for sex, age, and intervention groups; Model 3 adjusted as in Model 2 plus BMI, smoking status, family history of CHD, physical activity, hypertension, diabetes, dyslipidemia, and medication use: antihypertensive drugs, vitamins, insulin, oral hypoglycemic drugs, aspirin, or other antiplatelet drug; Model 4 was adjusted as in Model 3 plus 14-unit Mediterranean diet score.
Table 5: Sensitivity analysis of clinical cardiovascular risk factors.

|                  | Change in TG (mg/dL) | Change in GLU (mg/dL) | Change in DBP (mm Hg) |
|------------------|-----------------------|-----------------------|-----------------------|
|                  | N                     | Q₁ Mean SD            | Q₂ Mean SD            | Q₃ Mean SD | p<sup>a</sup>        | N         | Q₁ Mean SD | Q₂ Mean SD | Q₃ Mean SD | p<sup>a</sup> | N         | Q₁ Mean SD | Q₂ Mean SD | Q₃ Mean SD | p<sup>a</sup> |
| **Gender**       |                       |                       |                       |             |                     |           |             |             |             |             |           |             |             |             |             |
| Male             | 236                   | 6.41 43.58            | -17.86 62.54          | -14.80 44.68 | 0.007              | 2.35      | 38.03 35.56 | -0.32 35.99 | -6.12 35.99 | 0.36        | 1.24      | 10.04       | -2.43      | 9.73        | -2.14      | 11.67 0.714 |
| Female           | 249                   | 8.22 46.57            | 53.14 5.01            | 68.69 0.194  | 10.31               | 38.68     | 30.44 1.51  | 35.04 0.193 | 10.24 0.24  | -3.67 0.75  | -5.29      | 10.75       | -9.84 0.026 |
| **Age, years**   |                       |                       |                       |             |                     |           |             |             |             |             |           |             |             |             |             |
| ≤67              | 242                   | 8.71 47.80            | -9.75 70.39           | -8.77 62.27 | 0.089              | 7.08      | 41.13 1.56  | 30.86 0.82  | 36.48 0.262 | -0.64 0.7  | 9.70      | -1.41       | 10.78 0.77  | 11.73 0.396 |
| ≥68              | 243                   | 5.96 42.21            | -2.06 46.74           | -9.68 57.35 | 0.129              | 6.06      | 36.60 6.37  | 36.39 0.285 | 34.91 0.285 | -2.18 0.58  | -4.50      | 9.36        | -4.99 0.75  | 0.123       |
| P-14             |                       |                       |                       |             |                     |           |             |             |             |             |           |             |             |             |             |
| <9               | 274                   | -0.89 57.27           | -5.27 58.57           | -10.63 67.61 | 0.676              | 7.29      | 28.72 5.65  | 34.89 3.68  | 42.90 0.178 | -1.36 0.63  | 11.63     | -2.39       | 9.87 0.77  | 10.05 0.094 |
| ≥9               | 211                   | 12.07 35.90           | -6.49 61.19           | -8.33 53.71 | 0.007              | 6.18      | 43.25 2.69  | 32.89 -0.43 | 29.55 0.428 | -1.35 9.20  | -3.36      | 10.40       | -3.27 0.24  | 11.17       |

P-14: 14-point Mediterranean diet score test; GLU: glucose; TG: triglycerides; DBP: diastolic blood pressure.

<sup>a</sup> P value tested by ANOVA.

Values with asterisks are statistically different from the baseline by the paired-samples t-test ( * P < 0.05; ** P < 0.01).
inhibiting synthesis of the vasoconstrictor endothelin-1 (ET-1) in vascular endothelial cells [49]. Strong and positive association between polyphenol intake and plasma NO levels has been previously demonstrated by our group [8].

Some study limitations deserve to be noted. First, given that this substudy was conducted only among elderly subjects at high cardiovascular risk, it is difficult to extrapolate the results to the general population. Second, even though we adjusted potential confounders relative to CVD risk, residual confounding could still exist. Nonetheless, our study adds new evidence in support of a preventative effect of a long-term polyphenol intake on CVDs.

Compared with previous studies, the present study also has several strengths. Firstly, even though biomarkers are necessary to assess the compliance of the intervention, it is difficult to find a reliable and available biomarker. TPE in urine could be useful as a marker of compliance in intervention studies with foods with high-polyphenol content such as fruits, vegetables, wine, chocolate, tea, and coffee, while other markers are not suitable; moreover, in comparison with measuring the total polyphenol intake through self-reported information based on FFQ, the use of TPE, a biomarker of polyphenol intake, could provide more precise evidence [20, 50]. Secondly, the long duration of the intervention should also be considered as strength, since only few studies have tested associations between polyphenols and cardiovascular risk factors in such long-term intervention [8, 51, 52]. Thirdly, the selection of participants is a group of free-living individuals reproducing real-life conditions with home-prepared, energy-unrestricted foods. Fourthly, the Folin-Ciocalteu assay is a rapid, cheaper, and environmentally friendly measurement without requirement of dedicated instrumentation, which could be suggested to be applied in large intervention studies in the future.

In conclusion, in this 5-year study within the frame of the PREDIMED trial conducted in subjects at high cardiovascular risk, we found that polyphenol intake measured by TPE was inversely associated with some clinical cardiovascular risk factors, namely, plasma glucose and triglycerides concentrations and SBP, suggesting that intake of polyphenols provides protection against CVDs throughout these mechanisms. Further research is needed to confirm the current findings in the general population.

Disclosure
None of the funding sources played a role in the design, collection, analysis, or interpretation of the data or in the decision to submit the paper for publication.

Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments
This study was supported by CICYT (AGL2013-49083-C3-1-R) from the Spanish Ministry of Economy and Competitiveness (MEC), the Generalitat de Catalunya (GC) 2014 SGR 773 and Instituto de Salud Carlos III, ISCIII (CIBEROBN). CIBEROBN is an initiative of ISCIII, Spain. Xiaohui Guo received support from China Scholarship Council (CSC). Alexander Medina-Remón thanks the “Juan de la Cierva” postdoctoral program (JCI-2012-13463) from MEC. The Fundación Patrimonio Comunal Olivarero (Madrid, Spain), California Walnut Commission (Sacramento, CA), Borges SA (Reus, Spain), and Morella Nuts SA (Reus, Spain) donated the olive oil, walnuts, almonds, and hazelnuts, respectively, used in the study.

References
[1] D. Mozaffarian, E. J. Benjamin, A. S. Go et al., “Heart disease and stroke statistics—2015 update: a report from the American Heart Association,” Circulation, vol. 131, no. 4, pp. e29–e322, 2015.
[2] J. W. Eikelboom, E. Lonn, J. Genest Jr., G. Hankey, and S. Yusuf, “Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence,” Annals of Internal Medicine, vol. 131, no. 5, pp. 363–375, 1999.
[3] M. Marmot, “Cardiovascular disease,” Journal of Epidemiology and Community Health, vol. 47, no. 1, pp. 2–4, 1993.
[4] J. A. Vita, “Polyphenols and cardiovascular disease: effects on endothelial and platelet function,” The American Journal of Clinical Nutrition, vol. 81, no. 1, pp. 292–297, 2005.
[5] I. C. W. Arts and P. C. H. Hollman, “Polyphenols and disease risk in epidemiologic studies,” The American Journal of Clinical Nutrition, vol. 81, no. 1, pp. 317S–325S, 2005.
[6] M. Quírones, M. Miguel, and A. Alexandre, “Beneficial effects of polyphenols on cardiovascular disease,” Pharmacological Research, vol. 68, no. 1, pp. 125–131, 2013.
[7] M. Michalska, A. Głuba, D. P. Mikhailidis et al., “The role of polyphenols in cardiovascular disease,” Medical Science Monitor, vol. 16, no. 5, pp. RA110–RA119, 2010.
[8] A. Medina-Remón, A. Tresserra-Rimbau, A. Ponset et al., “Effects of total dietary polyphenols on plasma nitric oxide and blood pressure in a high cardiovascular risk cohort. The PREDIMED randomized trial,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 25, no. 1, pp. 60–67, 2015.
[9] J. Pérez-Jiménez, J. Hubert, L. Hooper et al., “Urinary metabolites as biomarkers of polyphenol intake in humans: a systematic review,” American Journal of Clinical Nutrition, vol. 92, no. 4, pp. 801–809, 2010.
[10] D. Huang, O. U. Boxin, and R. L. Prior, “The chemistry behind antioxidant capacity assays,” Journal of Agricultural and Food Chemistry, vol. 53, no. 6, pp. 1841–1856, 2005.
[11] A. Bláinski, G. C. Lopes, and J. C. P. De Mello, “Application and analysis of the folin-ciocalteu method for the determination of the total phenolic content from Limonium Brasiliense L.,” Molecules, vol. 18, no. 6, pp. 6852–6865, 2013.
[12] V. L. Singleton, R. Orthofer, and R. M. Lamuela-Raventós, “Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent,” Methods in Enzymology, vol. 299, pp. 152–178, 1999.
[13] A. Medina-Remón, R. Zamora-Ros, M. Rotchés-Ribalta et al., “Total polyphenol excretion and blood pressure in subjects at high cardiovascular risk,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 21, no. 5, pp. 323–331, 2011.
A. Medina-Remón, A. Barrionuevo-González, R. Zamora-Ros et al., "Rapid Folin-Ciocalteu method using microtiter 96-well plate cartridges for solid phase extraction to assess urinary total phenolic compounds, as a biomarker of total polyphenols intake," *Analytica Chimica Acta*, vol. 634, no. 1, pp. 54–60, 2009.

M. Farrás, R. M. Valls, S. Fernández-Castillejo et al., "Olive oil polyphenols enhance the expression of cholesterol efflux related genes in vivo in humans. A randomized controlled trial," *Journal of Nutritional Biochemistry*, vol. 24, no. 7, pp. 1334–1339, 2013.

B. Sarrià, S. Martínez-López, J. L. Sierra-Cinos, L. García-Díaz, R. Mateos, and L. Bravo, "Regular consumption of a cocoa product improves the cardiometabolic profile in healthy and moderately hypercholesterolaemic adults," *British Journal of Nutrition*, vol. 111, no. 1, pp. 122–134, 2014.

H.-C. Shin, S. H. Kim, Y. Park, B. H. Lee, and H. J. Hwang, "Effects of 12-week oral supplementation of Ecklonia cava polyphenols on anthropometric and blood lipid parameters in overweight Korean individuals: a double-blind randomized clinical trial," *Phytotherapy Research*, vol. 26, no. 3, pp. 363–368, 2012.

S. Almoosawi, L. Fyfe, C. Ho, and E. Al-Dujaili, "The effect of polyphenol-rich dark chocolate on fasting capillary whole blood glucose, total cholesterol, blood pressure and glucocorticoids in overweight obese subjects," *British Journal of Nutrition*, vol. 103, no. 6, pp. 842–850, 2010.

L. Shema-Didi, B. Kristal, S. Sela, R. Geron, and L. Ore, "Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients?" *Nutrition Journal*, vol. 13, article 18, 2014.

A. Tresserra-Rimbau, E. B. Rimm, A. Medina-Remón et al., "Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study," *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 24, no. 6, pp. 639–647, 2014.

N. V. Dhurandhar, D. Schoeller, A. W. Brown et al., "Energy balance measurement: when something is not better than nothing," *International Journal of Obesity*, vol. 39, pp. 1109–1133, 2015.

B. M. Davy and P. A. Estabrooks, "The validity of self-reported dietary intake data: focus on the ‘what we eat in America’ component of the national health and nutrition examination survey research initiative," *Mayo Clinic Proceedings*, vol. 90, no. 7, pp. 845–847, 2015.

E. Archer, G. Pavela, and C. J. Lavie, "The inadmissibility of what we eat in America and NHANES dietary data in nutrition and obesity research and the scientific formulation of national dietary guidelines," *Mayo Clinic Proceedings*, vol. 90, pp. 911–926, 2015.

J. P. E. Spencer, M. M. Abd El Mohsen, A.-M. Minihane, and J. C. Mathers, "Biomarkers of the intake of dietary polyphenols: strengths, limitations and application in nutrition research," *British Journal of Nutrition*, vol. 99, no. 1, pp. 12–22, 2008.

M. Á. Martínez-González, D. Corella, I. Salas-salvadó et al., "Cohort profile: design and methods of the PREDIMED Study," *International Journal of Epidemiology*, vol. 41, no. 2, pp. 377–385, 2012.

R. Estruch, E. Ros, J. Salas-Salvadó et al., "Primary prevention of cardiovascular disease with a Mediterranean diet," *The New England Journal of Medicine*, vol. 368, no. 14, pp. 1279–1290, 2013.

J. D. Fernández-Ballart, J. L. Piñol, I. Zazpe et al., "Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain," *British Journal of Nutrition*, vol. 103, no. 12, pp. 1808–1816, 2010.

M. A. Martínez-González, E. Fernández-Jarne, M. Serrano-Martínez, M. Wright, and E. Gomez-Gracia, "Development of a short dietary intake questionnaire for the quantitative estimation of adherence to a cardioprotective Mediterranean diet," *European Journal of Clinical Nutrition*, vol. 58, no. 11, pp. 1550–1552, 2004.

R. Elosua, J. Marrugat, L. Molina et al., "Validation of the Minnesota leisure time physical activity questionnaire in Spanish men," *American Journal of Epidemiology*, vol. 139, no. 12, pp. 1197–1209, 1994.

A. Tresserra-Rimbau, A. Medina-Remón, J. Pérez-Jiménez et al., "Dietary intake and major food sources of polyphenols in a Spanish population at high cardiovascular risk: the PREDIMED study," *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 23, no. 10, pp. 953–959, 2013.

P. Iglesias Bonilla, E. Mayoral Sánchez, J. Lapetra Peralta, M. Iborra Oquendo, F. Villalba Alcalá, and A. Cayuela Domínguez, "Validation of two systems of self-measurement of blood pressure, the OMRON HEM-705 CP and OMRON M1 (HEM 422C2-E) models," *Atencion Primaria*, vol. 30, no. 1, pp. 22–28, 2002.

W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge," *Chemical Medicine*, vol. 18, no. 6, pp. 499–502, 1972.

K. Hanhineva, R. Töröönen, I. Bondia-Pons et al., "Impact of dietary polyphenols on carbohydrate metabolism," *International Journal of Molecular Sciences*, vol. 11, no. 4, pp. 1365–1402, 2010.

G. Chiva-Blanch, M. Urpi-Sarda, E. Ros et al., "Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial," *Clinical Nutrition*, vol. 32, no. 2, pp. 200–206, 2013.

D. D. Mellor, T. Sathyapalan, S. Beckett, and S. L. Atkin, "High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients," *Diabetic Medicine*, vol. 27, no. 11, pp. 1318–1321, 2010.

L. Bozzetto, G. Annuzzi, G. Pacini et al., "Polyphenol-rich diets improve glucose metabolism in people at high cardiometabolic risk: a controlled randomised intervention trial," *Diabetologia*, vol. 58, no. 7, pp. 1551–1560, 2015.

K. Maruyama, H. Iso, S. Sasaki, and Y. Fukino, "The association between concentrations of green tea and blood glucose levels," *Journal of Clinical Biochemistry and Nutrition*, vol. 44, no. 1, pp. 41–45, 2009.

M. de Bock, J. G. B. Derwaik, C. M. Brennan et al., "Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trial," *PLoS ONE*, vol. 8, no. 3, Article ID e57622, 2013.

G. J. McDougall, F. Shpiro, P. Dobson, P. Smith, A. Blake, and D. Stewart, "Different polyphenolic components of soft fruits and -amylase and -glycosidase," *Journal of Agricultural and Food Chemistry*, vol. 53, no. 7, pp. 2760–2766, 2005.

K. Johnston, P. Sharp, M. Clifford, and L. Morgan, " Dietary polyphenols decrease glucose uptake by human intestinal Caco-2 cells," *FEBS Letters*, vol. 579, no. 7, pp. 1653–1657, 2005.

P. J. Carek and L. M. Dickerson, "Current concepts in the pharmacological management of obesity," *Drugs*, vol. 57, no. 6, pp. 883–904, 1999.
[42] H. Sugiyama, Y. Akazome, T. Shoji et al., “Oligomeric procyanidins in apple polyphenol are main active components for inhibition of pancreatic lipase and triglyceride absorption,” *Journal of Agricultural and Food Chemistry*, vol. 55, no. 11, pp. 4604–4609, 2007.

[43] T. L. Zern, K. L. West, and M. L. Fernandez, “Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs,” *Journal of Nutrition*, vol. 133, no. 7, pp. 2268–2272, 2003.

[44] A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure,” *Hypertension*, vol. 42, no. 6, pp. 1206–1252, 2003.

[45] L. J. Appel, T. J. Moore, E. Obarzanek et al., “A clinical trial of the effects of dietary patterns on blood pressure,” *The New England Journal of Medicine*, vol. 336, no. 16, pp. 1117–1124, 1997.

[46] A. Alonso, C. de la Fuente, A. M. Martín-Arnau, J. de Irala, J. A. Martínez, and M. Martínez-González, “Fruit and vegetable consumption is inversely associated with blood pressure in a Mediterranean population with a high vegetable-fat intake: the Seguimiento Universidad de Navarra (SUN) study,” *British Journal of Nutrition*, vol. 92, no. 2, pp. 311–319, 2004.

[47] N. Mohammadifard, A. Salehi-Abarghouei, J. Salas-Salvadó, M. Guasch-Ferré, K. Humphries, and N. Sarrafzadegan, “The effect of tree nut, peanut, and soy nut consumption on blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials,” *The American Journal of Clinical Nutrition*, vol. 101, no. 5, pp. 966–982, 2015.

[48] E. Toledo, F. B. Hu, R. Estruch et al., “Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial,” *BMC Medicine*, vol. 11, article 207, 2013.

[49] K. Yamagata, M. Tagami, and Y. Yamori, “Dietary polyphenols regulate endothelial function and prevent cardiovascular disease,” *Nutrition*, vol. 31, no. 1, pp. 28–37, 2015.

[50] A. Tresserra-Rimbau, E. B. Rimm, A. Medina-Remón et al., “Polyphenol intake and mortality risk: a re-analysis of the PREDIMED trial,” *BMC Medicine*, vol. 12, article 77, 2014.

[51] C. Manach, A. Mazur, and A. Scalbert, “Polyphenols and prevention of cardiovascular diseases,” *Current Opinion in Lipidology*, vol. 16, no. 1, pp. 77–84, 2005.

[52] Q. Sun, N. M. Wédick, S. S. Tworoger et al., “Urinary excretion of select dietary polyphenol metabolites is associated with a lower risk of type 2 diabetes in proximate but not remote follow-up in a prospective investigation in 2 cohorts of US women,” *Journal of Nutrition*, vol. 145, no. 6, pp. 1280–1288, 2015.